New hope for Hard-to-Treat myeloma: experimental drug tested in chinese patients

NCT ID NCT06934044

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510555, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, 325035, China
Tianjin Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 301636, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.